KRAKOW, Poland — Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel therapies that address emerging targets in oncology, today announced it will present preclinical data from its synthetic lethality pipeline at the 2025 AACR Annual Meeting, April 23-30, 2025, in Chicago, IL.
“We are excited to see continued progress across our preclinical pipeline. Our proprietary ONCO Prime platform has identified several novel synthetic lethal targets, including targets for KRAS-driven tumors, which offer immense potential to transform cancer treatment. Our work on next-generation ADCs targeting both synthetic lethality and immunocytotoxic mechanisms is advancing rapidly. At the same time, we continue to make significant strides in developing RVU305, our potentially best-in-class, brain-permeable MTA-cooperative PRMT5 inhibitor, with IND/CTA-enabling studies on track for completion in H2 2025. We are thrilled to present these advancements at the AACR Annual Meeting this year and look forward to engaging with the oncology community.” – said Krzysztof Brzózka, Ph.D., Chief Scientific Officer of Ryvu Therapeutics.
Details on the abstract presentations are as follows:
Abstract Title: “Preclinical candidate RVU305, an MTA-cooperative PRMT5 inhibitor,
shows activity in MTAP-deleted tumors resistant to immune checkpoint treatment”
Session Name: HDAC and Methyltransferase Inhibitors
Session date and time: Tuesday, April 29, 9:00 AM – 12:00 PM EST
Poster Number: 17 (board number), abstract number 4231
RVU305, a potentially best-in-class, brain-permeable MTA-cooperative PRMT5 inhibitor, demonstrates significant potential in targeting MTAP-deleted cancers. In preclinical studies, RVU305 effectively inhibited tumor growth in MTAP-null cancer models without affecting normal cells. Co-treatment with an anti-PD-1 antibody was well tolerated and resulted in antitumor activity in an MTAP-deleted, immune checkpoint inhibitors resistant model. The effects of RVU305, both alone and in combination with anti-PD-1, were supported by pharmacodynamic changes observed in tumor tissue. These results position RVU305 as a promising therapeutic option for patients carrying MTAP-deleted cancers resistant to immune checkpoint inhibitors treatment.
Abstract Title: “Discovery of novel synthetic lethal targets for effective and safe colorectal
cancer therapies”
Session Name: Experimental and Molecular Therapeutics
Session date and time: Monday, April 28, 2:00 PM – 5:00 PM EST
Poster Number: 3 (board number), abstract number 2973
This study highlights the discovery and validation of novel therapeutic targets for colorectal cancer (CRC) through synthetic lethal (SL) interactions, aiming to address the urgent need for more effective treatments. By using advanced models, including genetically engineered human intestinal stem cells (hISCs) and patient-derived xenografts (PDXs), combined with CRISPR/Cas9 technology, the team identified key vulnerabilities in CRC cells. Genome-wide screens revealed SL targets, particularly in genes associated with APC and KRAS mutations. These findings were validated both in vitro and in vivo, paving the way for the development of new, targeted therapies for CRC patients based on their unique mutational profiles.
All abstracts are now available online and can be obtained from the conference site:
https://www.aacr.org/
About Ryvu Therapeutics
Ryvu Therapeutics is a clinical-stage drug discovery and development company focused on novel oncology therapies that address emerging targets in oncology. Internally discovered pipeline candidates at Ryvu use diverse therapeutic mechanisms driven by emerging knowledge of cancer biology, including small molecules and antibody-drug conjugates directed at kinases, synthetic lethality, and immuno-oncology targets.
Ryvu’s most advanced program is RVU120, a selective CDK8/CDK19 kinase inhibitor with the potential to treat hematological malignancies. RVU120 is currently in Phase II development (i) in combination with venetoclax for the treatment of patients with r/r AML – the RIVER-81 study, (ii) as a monotherapy for the treatment of patients with lower-risk myelodysplastic syndromes (LR-MDS) – the REMARK study, (iii) as a monotherapy and in combination with ruxolitinib for the treatment of patients with myelofibrosis (MF) – the POTAMI-61 study. Dapolsertib (MEN1703, SEL24) is a dual PIM/FLT3 kinase inhibitor licensed to the Menarini Group that is currently being investigated in a Phase I study in diffuse large B-cell lymphoma (DLBCL) – the JASPIS-01 study. RVU305, a potentially best-in-class, brain-permeable PRMT5 inhibitor aiming to treat multiple solid tumors, is currently in IND/CTA-enabling studies. Ryvu Therapeutics is also engaged in oncology collaborations with BioNTech and Exelixis.
The company was founded in 2007 and is headquartered in Kraków, Poland. Ryvu is listed on the Warsaw Stock Exchange and is a component of the sWIG80 index.
Contact
Ryvu Therapeutics
Anna Wilk
+48 532 698 425
anna.wilk@ryvu.com